Browsing Tag
treatment-resistant depression
11 posts
Emyria (ASX: EMD) secures expanded Medibank (ASX: MPL) funding as insurer-backed mental health care enters Victoria
Find out how Medibank Private Ltd’s expanded funding supports Emyria Limited’s Victoria clinic and what it signals for insurer-backed mental health care.
What’s driving GH Research’s stock spike? FDA IND verdict looms for lead depression candidate
GH Research is set to update investors on its FDA IND filing and Phase 3 launch plans for GH001. Find out what this means for its future in depression treatment.
InhaleRx (ASX: IRX) unveils oral esketamine therapy for depression but stock sinks 22% amid investor caution
InhaleRx launches SRX-25 oral esketamine therapy for depression, plans rebrand and raises capital despite 22% stock plunge. Learn what this could mean for investors.
atai Beckley emerges as new global leader after atai Life Sciences and Beckley Psytech complete strategic merger in mental-health biotech
Find out how atai Life Sciences and Beckley Psytech’s merger to form atai Beckley is reshaping psychedelic biotech and transforming depression treatment.
Compass Pathways fast-tracks COMP360 launch timeline as Q3 2025 results show improved financial runway
Learn how Compass Pathways’ faster COMP360 launch timeline after Q3 2025 results could reshape the psychedelics industry and investor sentiment.
Are short-acting psychedelics the next big bet in mental health? What pharma’s billion-dollar moves suggest
Are short-acting psychedelics the future of psychiatry? Pharma’s billion-dollar bets say yes. We explore what’s behind the new wave of scalable mental health drugs.
Atai Life Sciences stock jumps 15% after Beckley Psytech trial update deepens investor interest in BPL-003
Atai Life Sciences stock surged 15% after positive BPL-003 trial data with Beckley Psytech. Investors eye Phase 3 momentum and merger milestones.
Is Emyria (ASX: EMD) stock ready to re-rate after Medibank funds its TRD program?
Emyria (ASX: EMD) secures Medibank backing for its TRD program, marking a milestone for insurer-funded mental health care. Can the stock sustain momentum?
Motif Neurotech secures UK grant to pioneer therapeutic brain-computer interface technology
Motif Neurotech, a Houston-based innovator in neurotechnology, has received a multimillion-dollar award from the UK’s Advanced Research and…
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as…